Pages that link to "Q47592938"

The following pages link to Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. (Q47592938):

Displaying 38 items.

• Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation (Q33418153) (← links)
• Hematopoietic stem cell transplantation for MDS. (Q33767314) (← links)
• Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes (Q34749088) (← links)
• The role of second transplants for leukemia (Q36204850) (← links)
• Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges (Q36266642) (← links)
• Second hematopoietic SCT for leukemia relapsing after myeloablative T cell-depleted transplants does not prolong survival (Q36961764) (← links)
• Subsequent donation requests among 2472 unrelated hematopoietic progenitor cell donors are associated with bone marrow harvest (Q37377933) (← links)
• Second hematopoietic stem cell transplantation in myeloid malignancies (Q37401234) (← links)
• Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transpl (Q37609957) (← links)
• Management of relapse after allo-SCT for AML and the role of second transplantation. (Q37621258) (← links)
• Relapse after allogeneic stem cell transplantation (Q37810125) (← links)
• Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation (Q37928360) (← links)
• Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status (Q37964938) (← links)
• Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. (Q38569175) (← links)
• Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation (Q38654516) (← links)
• The use of second allogeneic hematopoietic stem cell transplantation for hematologic malignancies relapsed after the first: Does it worth to do? (Q38774691) (← links)
• Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse (Q40208818) (← links)
• Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. (Q40313702) (← links)
• Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. (Q40466623) (← links)
• Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years (Q40519376) (← links)
• Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. (Q40542266) (← links)
• Immunotherapy following relapse of acute leukaemia after T-cell-replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft-versus-host disease (Q44325600) (← links)
• Outcomes following second allogeneic haematopoietic transplants using fludarabine-melphalan conditioning (Q48329297) (← links)
• Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation (Q50227222) (← links)
• Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation (Q51735777) (← links)
• Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party. (Q52960823) (← links)
• EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation (Q59351745) (← links)
• HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome (Q64074972) (← links)
• Adoptive immunotherapy, chemotherapy, and second allogeneic transplant in the treatment of post-transplant relapse of acute leukemia in children: a single center experience (Q85039033) (← links)
• When is second allogeneic HSCT for relapse of acute leukaemia an option? (Q86865002) (← links)
• [The consensus of allogeneic hematopoietic transplantation for hematological diseases in China(2016)-- post- transplant leukemia relapse] (Q88665506) (← links)
• Prevention and treatment of relapse after stem cell transplantation by cellular therapies (Q88797021) (← links)
• Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation (Q89108831) (← links)
• Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia (Q90168416) (← links)
• Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children (Q91168759) (← links)
• Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT (Q91329580) (← links)
• What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia? (Q92503484) (← links)
• Outcomes of second hematopoietic stem cell transplantation using reduced-intensity conditioning in an outpatient setting (Q99729195) (← links)